Clinical Trial

Celcuity adds Seagen commercial veteran Charles Romp to its board, a strategic move signaling its pivot from R&D to market readiness for gedatolisib.

Helsinki pioneers a revolutionary cancer therapy, offering new hope with a targeted neutron beam that destroys tumors in just one or two sessions.

In a landmark move, the FDA has removed major risk warnings from hormone therapy drugs, signaling a new era for women's health after decades of fear.

A 37-year-old patient receives a successful heart transplant at UCSF after being sustained by a SynCardia Total Artificial Heart, a major clinical win.

Clinical-stage biotech BioVie announces its novel anti-inflammatory drug, bezisterim, will be featured at a key psychiatric conference for its potential.

With promising new data for its cancer and obesity pipeline, Corbus Pharmaceuticals prepares for a crucial investor presentation at the Oppenheimer conference.

A new diagnostic tool for interstitial lung disease receives FDA Fast Track, promising earlier, more accurate detection of deadly lung inflammation.

With over $10M in new funding, Berlin Heals is advancing a novel implant that uses a gentle electrical field to potentially reverse heart failure damage.

The vaccine maker posts record 2025 earnings on mpox demand but signals a strategic shift, prioritizing its travel vaccine portfolio over new R&D.

The French biopharma giant posts strong 2025 results and forecasts over 13% growth, fueled by a booming pipeline and unexpected market advantages.

A potential first therapy for Charcot-Marie-Tooth disease heads to a major conference, showing promising functional gains despite missing its primary goal.

New data reveals Mesoblast's cell therapy Ryoncil dramatically boosts survival in GvHD patients when used early, paving the way for a major adult trial.

With a strong cash position, Arcus Biosciences heads into a pivotal year as investors await critical data on its promising cancer and autoimmune pipeline.

A 'world-first' cervical implant from Zavation Medical Products combines two materials to enhance bone growth while maintaining critical imaging capabilities.

A non-invasive device for spinal cord injury gains major international praise, signaling a shift in neurorehabilitation and a path to market.

Australian biotech Amplia Therapeutics is bringing its promising pancreatic cancer trial to the US, a key step in developing a drug that targets the disease's defenses.

After a decade-long battle with Stage 4 cancer, one patient's cure spotlights a revolutionary immunotherapy and its potential to change cancer treatment.

With its Phase 1 trial fully enrolled, Senti Bio’s logic-gated CAR-NK therapy shows deep, durable remissions, charting an expedited path for R/R AML.

Following key FDA progress for its oral osteoporosis drug, Entera Bio's CEO and board members are buying up company stock, signaling deep confidence.

Daré Bioscience launches telehealth for DARE to PLAY™, the first evidence-backed topical sildenafil cream designed to address female sexual arousal.